<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03492541</url>
  </required_header>
  <id_info>
    <org_study_id>CDMGD0012401</org_study_id>
    <nct_id>NCT03492541</nct_id>
  </id_info>
  <brief_title>Study of Efficacy and Tolerability of SYSTANE Complete in Patients With Dry Eye Disease</brief_title>
  <official_title>Evaluation of the Clinical Efficacy and Tolerability of SYSTANE Complete in Adult Patients With Dry Eye Disease Following Topical Ocular Use for 4 Weeks: A Multicenter Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the clinical effectiveness and tolerability of
      SYSTANE® Complete in adult patients with dry eye disease. Fluorescein-stained tear film
      break-up time (TFBUT) will be evaluated as the primary objective.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will attend 4 scheduled visits: Screening Visit (Day -7 to Day 0), Visit 1/Baseline
      Visit (Day 1), Visit 2 (Day 14) and Visit 3 (Day 28).

      This study is sponsored by Alcon, A Novartis Company.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 15, 2018</start_date>
  <completion_date type="Anticipated">December 17, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 14, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Tear Film Break-up Time (TFBUT) at Day 14</measure>
    <time_frame>Baseline, Day 14</time_frame>
    <description>TFBUT will be assessed using fluorescein, an ocular staining dye</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in dry eye symptom score at Day 1</measure>
    <time_frame>Baseline, Day 1</time_frame>
    <description>As reported by the patient using a Likert scale post drop instillation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Soothing sensation score</measure>
    <time_frame>Day 1</time_frame>
    <description>As reported by the patient using a Likert scale post drop instillation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability assessment score</measure>
    <time_frame>Day 1</time_frame>
    <description>As reported by the patient using an assessment questionnaire post drop instillation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in ocular discomfort at Day 14</measure>
    <time_frame>Baseline, Day 14</time_frame>
    <description>As reported by the patient using a Visual Analogue Scale (VAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in corneal staining score at Day 28</measure>
    <time_frame>Baseline, Day 28</time_frame>
    <description>Assessment of ocular staining using staining dye under a slit lamp</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in response to the revised IDEEL questionnaire at Day 28</measure>
    <time_frame>Baseline, Day 28</time_frame>
    <description>As reported by the patient using a subjective questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in EQ-5D-5L score(s) at Day 28</measure>
    <time_frame>Baseline, Day 28</time_frame>
    <description>As reported by the patient using a validated questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in TFBUT at Day 28</measure>
    <time_frame>Baseline, Day 28</time_frame>
    <description>TFBUT will be assessed using fluorescein, an ocular staining dye</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">134</enrollment>
  <condition>Dry Eye Disease</condition>
  <arm_group>
    <arm_group_label>SYSTANE Complete</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Propylene glycol-based eye drops, 1 drop in each eye twice a day (BID) (morning and evening) for 28 days. Patients can administer additional doses in between the scheduled daily doses as needed</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Propylene glycol-based eye drops</intervention_name>
    <description>Nano-emulsion ocular lubricant</description>
    <arm_group_label>SYSTANE Complete</arm_group_label>
    <other_name>SYSTANE® Complete</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must have TFBUT of ≤ 5 seconds in at least one eye at Screening visit.

          -  Must have best corrected visual acuity (BCVA) of ≥ 20/80 (or ≥ 55 letters score or ≥
             0.6 early treatment diabetic retinopathy study (ETDRS) log of the minimum angle of
             resolution (LogMAR) value) in both eyes at the Screening visit.

          -  Must be willing to discontinue use of all artificial tear supplements and use only the
             study product as directed for the entire study duration.

        Exclusion Criteria:

          -  History of hypersensitivity to the study drug or any of its excipients or to drugs of
             similar chemical classes.

          -  Use of any topical ocular medication preserved with benzalkonium chloride or other
             products known to be toxic to the tear film lipid layer within 1 month prior to the
             Screening visit.

        Other protocol-specified inclusion and exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alcon, A Novartis Company</last_name>
    <role>Study Director</role>
    <affiliation>Alcon, a Novartis Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Contact Alcon Call Center</last_name>
    <phone>1-888-451-3937</phone>
    <email>alcon.medinfo@alcon.com</email>
  </overall_contact>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 3, 2018</study_first_submitted>
  <study_first_submitted_qc>April 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2018</study_first_posted>
  <last_update_submitted>April 3, 2018</last_update_submitted>
  <last_update_submitted_qc>April 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mixed dry eye</keyword>
  <keyword>aqueous-deficient dry eye</keyword>
  <keyword>lipid-deficient dry eye</keyword>
  <keyword>evaporative dry eye</keyword>
  <keyword>tear film</keyword>
  <keyword>eye drops</keyword>
  <keyword>artificial tears</keyword>
  <keyword>lipid layer</keyword>
  <keyword>eye symptoms</keyword>
  <keyword>meibomian gland dysfunction</keyword>
  <keyword>MGD</keyword>
  <keyword>SYSTANE</keyword>
  <keyword>SYSTANE Complete</keyword>
  <keyword>nanoemulsion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Tetrahydrozoline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

